Selected article for: "cc international license and Middle east respiratory syndrome"
Author: Chi Heem Wong; Kien Wei Siah; Andrew W Lo
Title: Estimating Probabilities of Success of Clinical Trials for Vaccines and Other Anti-Infective Therapeutics
  • Document date: 2020_4_14
    • ID: fnrm6a79_18
    Snippet: A similar pattern can be seen for the non-industry-sponsored vaccine development programs; excluding the 'others' category, the top three most researched vaccine categories are also respiratory infections (24.8%), HIV (20.4%), and HBV (8.2%), whereas Middle East Respiratory Syndrome (MERS) and SARS are the least researched diseases with one development program each. CC-BY 4.0 International license It is made available under a author/funder, who h.....
    Document: A similar pattern can be seen for the non-industry-sponsored vaccine development programs; excluding the 'others' category, the top three most researched vaccine categories are also respiratory infections (24.8%), HIV (20.4%), and HBV (8.2%), whereas Middle East Respiratory Syndrome (MERS) and SARS are the least researched diseases with one development program each. CC-BY 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

    Search related documents:
    Co phrase search for related documents
    • development program and respiratory infection: 1, 2, 3
    • development program and vaccine development: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • development program and vaccine development program: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • industry sponsor and researched vaccine category: 1
    • industry sponsor and vaccine category: 1
    • industry sponsor and vaccine development: 1
    • international license and research disease: 1, 2
    • international license and respiratory infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • international license and similar pattern: 1, 2, 3, 4, 5, 6, 7
    • international license and vaccine development: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • research disease and respiratory infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • research disease and vaccine category: 1, 2
    • research disease and vaccine development: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • researched vaccine category and vaccine category: 1
    • researched vaccine category and vaccine development: 1
    • respiratory infection and similar pattern: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • respiratory infection and vaccine category: 1, 2
    • respiratory infection and vaccine development: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • similar pattern and vaccine development: 1, 2